ATE555200T1 - Verfahren und zusammensetzungen - Google Patents

Verfahren und zusammensetzungen

Info

Publication number
ATE555200T1
ATE555200T1 AT09708496T AT09708496T ATE555200T1 AT E555200 T1 ATE555200 T1 AT E555200T1 AT 09708496 T AT09708496 T AT 09708496T AT 09708496 T AT09708496 T AT 09708496T AT E555200 T1 ATE555200 T1 AT E555200T1
Authority
AT
Austria
Prior art keywords
polypeptide
methods
compositions
relates
attached
Prior art date
Application number
AT09708496T
Other languages
English (en)
Inventor
Gregory Winter
Christian Heinis
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE555200(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0802079.4A external-priority patent/GB0802079D0/en
Priority claimed from GB0818399A external-priority patent/GB0818399D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Application granted granted Critical
Publication of ATE555200T1 publication Critical patent/ATE555200T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
AT09708496T 2008-02-05 2009-02-04 Verfahren und zusammensetzungen ATE555200T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0802079.4A GB0802079D0 (en) 2008-02-05 2008-02-05 Method and compositions
GB0818399A GB0818399D0 (en) 2008-10-08 2008-10-08 Methods and compositions
PCT/GB2009/000301 WO2009098450A2 (en) 2008-02-05 2009-02-04 Methods and compositions

Publications (1)

Publication Number Publication Date
ATE555200T1 true ATE555200T1 (de) 2012-05-15

Family

ID=40792924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09708496T ATE555200T1 (de) 2008-02-05 2009-02-04 Verfahren und zusammensetzungen

Country Status (11)

Country Link
US (3) US8680022B2 (de)
EP (5) EP2474613B2 (de)
JP (2) JP6074574B2 (de)
AT (1) ATE555200T1 (de)
AU (1) AU2009211253B2 (de)
CA (1) CA2714477C (de)
DK (2) DK2257624T5 (de)
ES (2) ES2383191T3 (de)
PL (1) PL2257624T3 (de)
PT (1) PT2257624E (de)
WO (1) WO2009098450A2 (de)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
JP2013518558A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 構造化されたペプチドプロセシング
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
JP6092104B2 (ja) * 2010-08-13 2017-03-08 ミティ・バイオシステムズ・ゲーエムベーハー 修飾ペプチドディスプレイ
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
RS57996B1 (sr) 2011-06-30 2019-01-31 Genzyme Corp Inhibitori aktivacije t-ćelija
RU2631931C2 (ru) 2011-10-07 2017-09-28 Байсикл Терапьютикс Лимитед Модуляция специфичности структурированных белков
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
EP2810069A4 (de) 2012-02-03 2015-08-12 Univ Alberta Verfahren zur quantifizierung von peptidderivatbibliotheken mittels phagenanzeige
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
SG10201807059QA (en) 2012-05-10 2018-09-27 Massachusetts Inst Technology Agents for influenza neutralization
EP2882453B1 (de) 2012-08-07 2021-01-06 Massachusetts Institute of Technology Antikörper gegen das denguevirus und verwendungen davon
WO2014055836A2 (en) 2012-10-04 2014-04-10 Research Development Foundation Serine protease molecules and therapies
JP6408480B2 (ja) 2012-11-30 2018-10-17 ノバルティス アーゲー ジスルフィドを含むタンパク質から複合体を調製する方法
GB201306623D0 (en) * 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
EP2999483B1 (de) * 2013-05-23 2018-10-31 Ohio State Innovation Foundation Chemische synthese und screening von bicyclischen peptidbibliotheken
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
EA201690388A1 (ru) 2013-08-14 2016-07-29 Уильям Марш Райс Юниверсити Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
US10294274B2 (en) * 2013-10-28 2019-05-21 Bicyclerd Limited Polypeptide ligands specific for plasma kallikrein
US9902764B2 (en) 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
US10822604B2 (en) 2014-05-02 2020-11-03 Morphosys Ag Peptide libraries
GB201413086D0 (en) 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
AU2015336857B2 (en) 2014-10-22 2020-04-09 The Governors Of The University Of Alberta Genetic encoding of chemical post-translational modification for phage-displayed libraries
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
KR101693665B1 (ko) * 2014-11-13 2017-01-06 목포해양대학교 산학협력단 설치와 철거가 용이한 구조를 가지는 기초의 세굴방지장치 및 이를 이용한 기초의 세굴방지방법
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
JP6609099B2 (ja) * 2014-12-10 2019-11-20 キヤノン株式会社 放射線検出装置、及び放射線検出シート
AU2015371172B2 (en) 2014-12-22 2021-05-13 Lanthiopep B.V. Novel methods for displaying cyclic peptides on bacteriophage particles
US20160312212A1 (en) * 2015-04-23 2016-10-27 Roche Sequencing Solutions, Inc. Cow antibody scaffold polypeptide method and composition
JP2015214568A (ja) * 2015-07-13 2015-12-03 バイスクル・セラピューティクス・リミテッド 多重特異性ペプチド
WO2017143026A1 (en) 2016-02-16 2017-08-24 Research Development Foundation Sortase-modified molecules and uses thereof
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
JP7093300B2 (ja) 2016-06-07 2022-06-29 株式会社カネカ リボソームディスプレイ複合体およびその製造方法
US11351222B2 (en) 2016-11-09 2022-06-07 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
WO2018098226A1 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
WO2018098282A2 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
EP3544621A1 (de) 2016-11-27 2019-10-02 BicycleRD Limited Verfahren zur behandlung von krebs
WO2018106112A1 (en) 2016-12-06 2018-06-14 Stichting Voor De Technische Wetenschappen Multicyclic peptides and methods for their preparation
JP2020502238A (ja) * 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
KR20230042153A (ko) * 2016-12-23 2023-03-27 바이사이클티엑스 리미티드 Ｍｔ１－ｍｍｐ에 대한 결합용 펩티드 리간드
EP3565638B8 (de) 2017-01-06 2024-04-10 BicycleRD Limited Bizyklische konjugat zur behandlung von krebs
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (de) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclische peptidliganden und ihre verwendungen
CA3064512A1 (en) 2017-06-09 2018-12-13 Vib Vzw Glutamine dehydrogenase inhibitors for use in muscle regeneration
EP3645549A1 (de) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclische peptidliganden mit nachweisbaren anteilen und deren verwendung
PL3655013T3 (pl) 2017-07-17 2022-08-22 Vib Vzw Ukierunkowanie na synaptogirynę-3 w leczeniu tauopatii
WO2019025811A1 (en) 2017-08-04 2019-02-07 Bicycletx Limited SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
US20200283482A1 (en) 2017-08-14 2020-09-10 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
EP3701259A1 (de) 2017-10-26 2020-09-02 VIB vzw Podoplaninpositive makrophagen
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
EP3752200A1 (de) 2018-02-13 2020-12-23 Vib Vzw Targeting minimaler resterkrankung bei krebs mit rxr-antagonisten
MX2020008791A (es) 2018-02-23 2021-01-08 Bicycletx Ltd Ligandos de peptidos biciclicos multimericos.
KR20200139236A (ko) 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
GB201808835D0 (en) * 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
KR20210038592A (ko) * 2018-07-23 2021-04-07 더 거버너스 오브 더 유니버시티 오브 알버타 유전자 인코딩된 이환형 펩타이드 라이브러리
US11655468B2 (en) 2018-07-25 2023-05-23 The Trustees Of Boston College Methods and compositions of chemically modified phage libraries
WO2020023620A1 (en) * 2018-07-25 2020-01-30 Trustees Of Boston College Methods and compositions of chemically modified phage libraries
JP2022512779A (ja) 2018-10-23 2022-02-07 バイスクルテクス・リミテッド 二環式ペプチドリガンドおよびその使用
GB201819659D0 (en) 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
SG11202106081YA (en) 2018-12-13 2021-07-29 Bicycletx Ltd Bicyclic peptide ligands specific for mt1-mmp
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
US20220088207A1 (en) 2018-12-21 2022-03-24 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900529D0 (en) * 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
AU2020253990A1 (en) 2019-04-02 2021-10-28 Bicycletx Limited Bicycle toxin conjugates and uses thereof
JP2022532134A (ja) 2019-05-09 2022-07-13 バイスクルテクス・リミテッド Ｏｘ４０に特異的な二環式ペプチドリガンド
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
EP3976067A1 (de) 2019-05-28 2022-04-06 Vib Vzw Cd8+-t-zellen ohne plexine und ihre anwendung zur krebsbehandlung
TW202118770A (zh) 2019-07-30 2021-05-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220363713A1 (en) 2019-08-07 2022-11-17 Belyntic GmbH A method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules
WO2021028686A1 (en) 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
EP4038096A1 (de) 2019-10-03 2022-08-10 BicycleTX Limited Bicyclische peptidkomplexe mit heteroatomen
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
MX2022006001A (es) 2019-11-27 2022-10-27 Bicycletx Ltd Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos.
JP2023506083A (ja) 2019-12-16 2023-02-14 バイスクルテクス・リミテッド Ｉｌ－１７に特異的な二環式ペプチドリガンド
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
CN110907422B (zh) * 2019-12-16 2021-07-06 吉林大学 基于Ti3C2的凝血酶适体传感器及其制备方法
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918558D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
WO2021205161A1 (en) 2020-04-06 2021-10-14 Bicycletx Limited Bicyclic peptide ligands specific for tslp
WO2021220011A1 (en) 2020-05-01 2021-11-04 Bicycletx Limited Anti-infective bicyclic peptide conjugates
WO2021229238A1 (en) 2020-05-15 2021-11-18 Bicycletx Limited Anti-infective bicyclic peptide ligands
IL298868A (en) 2020-06-12 2023-02-01 Bicycletx Ltd Treatment of diseases characterized by overexpression of hepatocyte receptor A2 that produces erythropoietin (EPHA2)
BR112023001428A2 (pt) 2020-08-03 2023-02-23 Bicycletx Ltd Ligantes à base de peptídios
CN111893577B (zh) * 2020-08-06 2022-03-22 厦门大学 基于4-羟基-2,6-二氟-1,3,5-苯三腈构建噬菌体展示环肽库的方法
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
EP4216943A1 (de) 2020-09-24 2023-08-02 Vib Vzw Kombination von p2y6-inhibitoren und immuncheckpoint-inhibitoren
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
KR20230107589A (ko) 2020-11-13 2023-07-17 바이사이클티엑스 리미티드 트랜스페린 수용체 1 (TfR1)에 특이적인 비시클릭 펩티드 리간드
US20240197897A1 (en) 2021-01-08 2024-06-20 Bicycle TX Limited Heterotandem bicyclic peptide complexes
JP2024504068A (ja) 2021-01-08 2024-01-30 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
WO2022148968A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
WO2022148974A2 (en) 2021-01-08 2022-07-14 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
JP2024504074A (ja) 2021-01-08 2024-01-30 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
US20240083944A1 (en) 2021-01-08 2024-03-14 Bicycle TX Limited Anti-infective bicyclic peptide ligands
AU2022205795A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Anti-infective bicyclic peptide ligands
US20240325554A1 (en) 2021-01-11 2024-10-03 Bicycle TX Limited Methods for treating cancer
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
EP4294407A1 (de) 2021-02-17 2023-12-27 Vib Vzw Hemmung von slc4a4 bei der behandlung von krebs
WO2022195287A1 (en) 2021-03-19 2022-09-22 Bicycletx Limited Bicyclic peptide ligands specific for trem2
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
EP4326743A1 (de) 2021-04-20 2024-02-28 BicycleTX Limited Für p-selectin spezifische bicyclische peptidliganden
CA3227511A1 (en) 2021-08-06 2023-02-09 Lætitia LINARES Methods for the treatment of cancer
AU2022340959A1 (en) 2021-09-03 2024-03-07 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
AU2022357561A1 (en) 2021-10-01 2024-04-18 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
GB202114279D0 (en) 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
GB202116263D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Anti-infective bicyclic peptide ligands
GB202116266D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Novel use
CN114166924A (zh) * 2021-12-03 2022-03-11 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy
GB202206431D0 (en) 2022-05-03 2022-06-15 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
WO2024009108A1 (en) 2022-07-07 2024-01-11 Bicycletx Limited Anti-infective bicyclic peptide ligands
WO2024160756A1 (en) 2023-01-30 2024-08-08 Vib Vzw Suppressors of tauopathies
WO2024184661A1 (en) 2023-03-09 2024-09-12 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313509D0 (en) * 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1998036743A1 (en) * 1997-02-21 1998-08-27 Cypros Pharmaceutical Corporation Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
IL142025A0 (en) 1999-07-20 2002-03-10 Morphosys Ag Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
WO2001023619A1 (en) * 1999-09-29 2001-04-05 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
WO2002077182A2 (en) * 2001-03-21 2002-10-03 Xenoport, Inc. Compounds displayed on icosahedral phage and methods of using same
EP1504111A4 (de) 2002-04-19 2005-11-23 California Inst Of Techn Peptide mit unnatürlichen aminosäureresten enthaltende nukleinsäure-peptid-display-bibliotheken und verfahren zur herstellung davon
EP1452868A2 (de) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Verfahren zur Selektion eines potenziellen Arzneimittels
CA2595902C (en) * 2005-01-24 2017-08-22 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors
WO2006095345A2 (en) * 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
JP2009544697A (ja) * 2006-07-26 2009-12-17 ペプスキャン システムズ ベー．フェー． 免疫原性化合物及びタンパク質擬態物
AU2007336132A1 (en) * 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular CCR5 peptide conjugates and uses thereof

Also Published As

Publication number Publication date
EP2653544A1 (de) 2013-10-23
EP2257624B1 (de) 2012-04-25
EP2257624A2 (de) 2010-12-08
WO2009098450A2 (en) 2009-08-13
ES2383191T9 (es) 2012-10-16
CA2714477C (en) 2018-10-16
PL2257624T3 (pl) 2012-09-28
ES2509959T3 (es) 2014-10-20
ES2383191T3 (es) 2012-06-19
DK2257624T5 (da) 2012-09-10
DK2257624T3 (da) 2012-05-29
US20150166988A1 (en) 2015-06-18
EP2257624B9 (de) 2012-08-01
CA2714477A1 (en) 2009-08-13
PT2257624E (pt) 2012-05-29
EP2474613B1 (de) 2014-07-16
US8680022B2 (en) 2014-03-25
AU2009211253B2 (en) 2014-11-06
JP2011514803A (ja) 2011-05-12
EP2653545A1 (de) 2013-10-23
US20100317547A1 (en) 2010-12-16
EP2474613A1 (de) 2012-07-11
JP2015109856A (ja) 2015-06-18
US9657288B2 (en) 2017-05-23
WO2009098450A3 (en) 2009-10-29
JP6074574B2 (ja) 2017-02-08
US20140187757A1 (en) 2014-07-03
US9670484B2 (en) 2017-06-06
JP6075658B2 (ja) 2017-02-08
EP2474613B2 (de) 2022-02-16
DK2474613T3 (da) 2014-10-06
AU2009211253A1 (en) 2009-08-13
EP2653543A1 (de) 2013-10-23

Similar Documents

Publication Publication Date Title
ATE555200T1 (de) Verfahren und zusammensetzungen
EA201170168A1 (ru) Комплекс (минерал-аминокислота)-полисахарид
DE502007007088D1 (de) Ierte hydroformylierung
MX2009007695A (es) Compuestos complejos de carbohidrato de hierro.
NZ603495A (en) Algorithm for designing irreversible inhibitors
MX2008012627A (es) Metodos para producir materiales de estructura metalica-organica conteniendo metales del subgrupo iv.
ATE453634T1 (de) Regioselektives verfahren zur zubereitung von benzimidazol-thiophenen
MX2012005527A (es) Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
EA201071201A1 (ru) ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71
DK2346994T3 (da) Knock-in-mus til fremstilling af kimære antistoffer
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
MX2013005075A (es) Compuestos antidiabeticos.
EP2147936A4 (de) Neuartige lebende radikalpolymerisation mit phosphorverbindung oder stickstoffverbindung als katalysator
ATE496914T1 (de) Verfahren zur synthese von triazolen
DE10701504T8 (de) Verfahren zur herstellung von pulverisierter kohle
WO2012078313A3 (en) Gb1 peptidic libraries and compounds, and methods of screening the same
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
GB201315932D0 (en) Catalyst compositions containing transition metal complexes with thiolate ligands
EA201400124A1 (ru) Крупномасштабное производство станнсопорфина высокой чистоты
TW200631939A (en) Process for cross coupling indoles
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
ATE529413T1 (de) Verfahren zur synthese von aryloxydiaminopyrimidinen
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
WO2010056585A3 (en) Heteroaryl diamide compounds useful as mmp-13 inhibitors